DEA proposes moving three sleep medications to a less restrictive drug schedule
/ 1 min read
Table of Contents
The Drug Enforcement Administration (DEA) has proposed changing how three specific drugs—suvorexant, lemborexant, and daridorexant—are classified under the Controlled Substances Act. These are medications used to treat insomnia.
Why it matters: This is primarily an administrative change that reduces the level of federal control over these specific sleep medications.
Who it affects
- Pharmaceutical manufacturers and distributors of suvorexant, lemborexant, and daridorexant
This is a proposed rule from the Drug Enforcement Administration; readers should consult the Federal Register before relying on this information.
Agency: Justice Department, Drug Enforcement Administration
Source: Federal Register — read the official document